Boston Scientific (BSX) Stock Forecast & Price Target

$47.85 +0.05 (+0.10%)

As of 09/4/2026 03:58 PM Eastern

Compare

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 31 Analyst Ratings

Sell
2

Hold
5

Buy
24

Based on 31 Wall Street analysts who have issued ratings for Boston Scientific in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 31 analysts, 2 have given a sell rating, 5 have given a hold rating, and 24 have given a buy rating for BSX.

Consensus Price Target

$71.62
49.67% Upside

According to the 31 analysts' twelve-month price targets for Boston Scientific, the average price target is $71.62. The highest price target for BSX is $118.00, while the lowest price target for BSX is $50.00. The average price target represents a forecasted upside of 49.67% from the current price of $47.85.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BSX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Boston Scientific and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BSX Analyst Ratings Over Time

Type	Current Forecast 9/8/25 to 9/8/26	1 Month Ago 8/9/25 to 8/9/26	3 Months Ago 6/10/25 to 6/10/26	1 Year Ago 9/8/24 to 9/8/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)	3 Strong Buy rating(s)
Buy	24 Buy rating(s)	24 Buy rating(s)	22 Buy rating(s)	21 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)	1 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$71.62	$71.62	$85.92	$117.79
Forecasted Upside	49.67% Upside	45.11% Upside	77.43% Upside	8.93% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

BSX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BSX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Boston Scientific Stock vs. The Competition

Type	Boston Scientific	Healthcare Companies	Broader Market
Consensus Rating Score	2.71	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	49.67% Upside	928.67% Upside	14.03% Upside
News Sentiment Rating	Positive News See Recent BSX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
8/25/2026	TD Cowen 3 of 5 stars	Joshua Jennings Not Rated	Reiterated Rating	Buy	$56.00	+14.32%
7/31/2026	Argus 3 of 5 stars	David Toung 4 of 5 stars	Reiterated Rating	Buy ➝ Hold
7/30/2026	Royal Bank Of Canada 3 of 5 stars	Shagun Singh 3 of 5 stars	Lower Target	Outperform	$85.00 ➝ $70.00	+54.19%
7/30/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$74.00 ➝ $67.00	+47.58%
7/30/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy	$60.00	+34.09%
7/30/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$56.00	+21.57%
7/30/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$70.00 ➝ $66.00	+47.50%
7/30/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$55.00 ➝ $50.00	+8.54%
7/30/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$60.00	+30.25%
7/30/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$70.00 ➝ $61.00	+32.42%
Elon Musk's next big bet has nothing to do with rockets (Ad) Elon Musk's next major bet isn't rockets, it's a light speed technology making AI 100 times faster and more energy efficient. Jensen Huang just committed 7.2 billion dollars to the same trend, and related stocks have already surged 133 percent, 217 percent, and 320 percent in recent months, according to Jason Bodner's research at Inflection Point. Reveal Jason Bodner's number one Accelerated AI stock pick free
7/30/2026	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$57.00	+23.74%
7/30/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$62.00 ➝ $57.00	+26.36%
7/29/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$60.00	+30.25%
7/29/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$65.00 ➝ $60.00	+29.99%
7/27/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suraj Kalia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$90.00 ➝ $85.00	+89.56%
7/15/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$90.00 ➝ $70.00	+63.75%
7/8/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$77.00 ➝ $57.00	+25.84%
7/7/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold (C-) ➝ Sell (D+)
7/6/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$65.00	+47.17%
6/24/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$100.00 ➝ $67.00	+49.84%
6/12/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$65.00	+37.67%
6/5/2026	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold ➝ Strong Sell
5/29/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/28/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$71.00	+44.81%
5/28/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$96.00 ➝ $89.00	+76.79%
5/18/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bob Hopkins Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$105.00 ➝ $68.00	+22.86%
4/29/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
2/6/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$112.00	+43.53%
2/5/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$135.00 ➝ $100.00	+27.61%
2/5/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$130.00 ➝ $118.00	+56.29%
2/2/2026	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$115.00	+24.35%
10/3/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:23 AM ET.

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, September 5, 2026. Please send any questions or comments about these Boston Scientific pros and cons to contact@marketbeat.com.

Boston Scientific
Bull Case

Here are some ways that investors could benefit from investing in Boston Scientific Co.:

Boston Scientific Co. is currently trading at $47.85, a significant discount to the consensus price target of $71.62, suggesting substantial upside potential for investors who believe the recent negative news has been overreacted to by the market.
The company's management has demonstrated strong confidence in the stock's value by authorizing a $5.00 billion share buyback program, which allows the company to repurchase up to 6.4% of its outstanding shares, a move that typically signals that leadership believes the stock is undervalued.
Boston Scientific Co. recently beat its quarterly earnings expectations, reporting $0.86 in earnings per share against a consensus estimate of $0.83, while also exceeding revenue forecasts with $5.44 billion in sales, indicating that the core business remains fundamentally strong despite recent operational challenges.
The company's interventional cardiology and vascular therapy business is showing strong momentum, with sales increasing by 15% driven by demand for coronary therapies and new devices, providing a solid growth engine that can help offset pressures in other parts of the business.
Institutional investors are showing renewed interest in the stock, with several funds including AlphaGrep UK Ltd and Nykredit A S establishing new positions or significantly increasing their holdings in the second quarter, suggesting that professional money is beginning to accumulate shares at current levels.

Boston Scientific
Bear Case

Investors should be bearish about investing in Boston Scientific Co. for these reasons:

The company is facing significant operational and financial risks from a recent cyberattack that disrupted global shipping operations, which could lead to lost revenue and increased costs as it works to restore normal business functions and secure its digital infrastructure.
Boston Scientific Co. has issued multiple worldwide product recalls, including the Infinion CX spinal-cord-stimulator leads due to fracture risks following 1,081 injury reports, which creates substantial liability exposure, regulatory scrutiny, and potential damage to the company's brand reputation.
The stock has experienced a severe decline, hitting a 52-week low of $42.20, and is currently trading well below its 200-day moving average of $55.74, indicating a strong downward trend and significant investor caution regarding the company's future performance.
Analysts have lowered their price targets and some have downgraded the stock, with Zacks Research issuing a "strong sell" rating and others reducing their targets from the $70-$77 range to the $57-$61 range, reflecting a consensus view that the company's 2026 outlook is weaker than previously expected.
The company's guidance for the full year 2026 has been lowered to $3.280-$3.320 in earnings per share, which is below the previous consensus estimate of $3.360, signaling that management expects continued pressure on profitability and revenue growth in the coming year.

BSX Forecast - Frequently Asked Questions

According to the research reports of 31 Wall Street equities research analysts, the average twelve-month stock price forecast for Boston Scientific is $71.62, with a high forecast of $118.00 and a low forecast of $50.00.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Boston Scientific in the last year. There are currently 2 sell ratings, 5 hold ratings and 24 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BSX shares.

According to analysts, Boston Scientific's stock has a predicted upside of 49.67% based on their 12-month stock forecasts.

Over the previous 90 days, Boston Scientific's stock had 1 downgrade by analysts.

Boston Scientific has been rated by research analysts at Argus, BTIG Research, Canaccord Genuity Group, Citigroup, Deutsche Bank Aktiengesellschaft, Evercore, Jefferies Financial Group, Leerink Partners, Mizuho, Needham & Company LLC, Oppenheimer, Piper Sandler, Raymond James Financial, Robert W. Baird, Royal Bank Of Canada, Stifel Nicolaus, TD Cowen, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Boston Scientific more than other "healthcare" companies. The consensus rating for Boston Scientific is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how BSX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Boston Scientific Recommendations

MarketBeat monitors more than a dozen sources for Boston Scientific analyst ratings, with the most recent rating issued on 8/25/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BSX Analyst Ratings Over Time

BSX Analyst Recommendations By Month

BSX Price Targets by Month

Boston Scientific Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

Boston Scientific
Bull Case

Boston Scientific
Bear Case

BSX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Boston Scientific Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BSX Analyst Ratings Over Time

BSX Analyst Recommendations By Month

BSX Price Targets by Month

Boston Scientific Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Boston Scientific Stock? BSX Pros and Cons Explained

Boston Scientific Bull Case

Boston Scientific Bear Case

BSX Forecast - Frequently Asked Questions

What is Boston Scientific's forecast for 2026?

Should I buy or sell Boston Scientific stock right now?

Does Boston Scientific's stock price have much upside?

Has Boston Scientific been downgraded by Wall Street analysts recently?

What analysts cover Boston Scientific?

Do Wall Street analysts like Boston Scientific more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Boston Scientific Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Boston Scientific
Bull Case

Boston Scientific
Bear Case